The RSA Group was pleased to partner with Oxford BioMedica to secure the appointment of Stuart Paynter as Chief Financial Officer.  Starting in August 2017, Mr. Paynter will also join the Board.

Nick Stephens of The RSA Group commented,”The outgoing CFO Tim Watts has helped lead Oxford BioMedica to its current leadership position in Cell & Gene Therapy and we look forward to Stuart taking up the reins for the next stage of the journey.”

Read the full release:

Share this: